{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:28:31Z","timestamp":1781602111129,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T00:00:00Z","timestamp":1225756800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/ijo.2008.189","type":"journal-article","created":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T10:03:50Z","timestamp":1225793030000},"page":"1752-1763","source":"Crossref","is-referenced-by-count":40,"title":["Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review"],"prefix":"10.1038","volume":"32","author":[{"given":"M","family":"Neovius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Narbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,4]]},"reference":[{"key":"BFijo2008189_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1001\/archinte.161.13.1581","volume":"161","author":"AE Field","year":"2001","unstructured":"Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581\u20131586.","journal-title":"Arch Intern Med"},{"key":"BFijo2008189_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMoa055643","volume":"355","author":"KF Adams","year":"2006","unstructured":"Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50\u201371 years old. N Engl J Med 2006; 355: 763\u2013778.","journal-title":"N Engl J Med"},{"key":"BFijo2008189_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1467-789X.2006.00248.x","volume":"8","author":"I Janssen","year":"2007","unstructured":"Janssen I, Mark AE . Elevated body mass index and mortality risk in the elderly. Obes Rev 2007; 8: 41\u201359.","journal-title":"Obes Rev"},{"key":"BFijo2008189_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa054017","volume":"355","author":"SH Jee","year":"2006","unstructured":"Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355: 779\u2013787.","journal-title":"N Engl J Med"},{"key":"BFijo2008189_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/ijo.2008.70","volume":"32","author":"M Neovius","year":"2008","unstructured":"Neovius M, Kark M, Rasmussen F . Association between obesity status in young adulthood and disability pension. Int J Obes (Lond) 2008; 32: 1319\u20131326.","journal-title":"Int J Obes (Lond)"},{"key":"#cr-split#-BFijo2008189_CR6.1","doi-asserted-by":"crossref","unstructured":"1. Neovius K, Johansson K, Rossner S, Neovius M . Disability pension, employment and obesity status: a systematic review. Obes Rev 2008","DOI":"10.1111\/j.1467-789X.2008.00502.x"},{"key":"#cr-split#-BFijo2008189_CR6.2","unstructured":"2. e-pub ahead of print 1 June 2008. PMID: 18518906."},{"key":"BFijo2008189_CR7","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/archinte.162.18.2061","volume":"162","author":"K Narbro","year":"2002","unstructured":"Narbro K, \u00c5gren G, Jonsson E, N\u00e4slund I, Sj\u00f6str\u00f6m L, Peltonen M . Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162: 2061\u20132069.","journal-title":"Arch Intern Med"},{"key":"BFijo2008189_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archinte.158.5.466","volume":"158","author":"CP Quesenberry Jr","year":"1998","unstructured":"Quesenberry Jr CP, Caan B, Jacobson A . Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466\u2013472.","journal-title":"Arch Intern Med"},{"key":"BFijo2008189_CR9","first-page":"895","volume":"20","author":"K Narbro","year":"1996","unstructured":"Narbro K, Jonsson E, Larsson B, Waaler H, Wedel H, Sj\u00f6str\u00f6m L . Economic consequences of sick-leave and early retirement in obese Swedish women. Int J Obes Relat Metab Disord 1996; 20: 895\u2013903.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFijo2008189_CR10","unstructured":"IOTF. Prevalence of Adult Obesity. Available at http:\/\/iotf.org\/database\/GlobalAdultTableJune07.htm , 2007."},{"key":"BFijo2008189_CR11","first-page":"i","volume":"894","author":"WHO","year":"2000","unstructured":"WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i\u2013xii, 1\u2013253.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"BFijo2008189_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa066254","volume":"357","author":"L Sjostrom","year":"2007","unstructured":"Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741\u2013752.","journal-title":"N Engl J Med"},{"key":"BFijo2008189_CR13","doi-asserted-by":"crossref","unstructured":"Curioni C, Andre C . Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006: CD006162.","DOI":"10.1002\/14651858.CD006162.pub2"},{"key":"BFijo2008189_CR14","doi-asserted-by":"crossref","unstructured":"Padwal R, Li SK, Lau DC . Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004: CD004094.","DOI":"10.1002\/14651858.CD004094.pub2"},{"issue":"November 17","key":"BFijo2008189_CR15","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen P, Bartels E, Bliddal H, Astrup A . Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370 (November 17): 1706\u20131713.","journal-title":"Lancet"},{"key":"BFijo2008189_CR16","unstructured":"FDA. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant). Advisory Committee\u201413 June, 2007. pp 1\u201388. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4306b1-fda"},{"key":"BFijo2008189_CR17","unstructured":"NICE. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children, 2006. NICE clinical guideline 43, NHS: London, pp 1\u201384. Available at: http:\/\/www.nice.org.uk\/Guidance\/CG43"},{"key":"BFijo2008189_CR18","unstructured":"NICE. Rimonabant for the treatment of overweight and obese adults, 2008. NICE technology appraisal guidance 144. NHS: London, available at: http:\/\/www.nice.org.uk\/Guidance\/CG43"},{"key":"BFijo2008189_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1467-789X.2007.00352.x","volume":"8","author":"R Ara","year":"2007","unstructured":"Ara R, Brennan A . The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. Obes Rev 2007; 8: 363\u2013371.","journal-title":"Obes Rev"},{"key":"BFijo2008189_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10198-006-0374-x","volume":"7","author":"A Brennan","year":"2006","unstructured":"Brennan A, Ara R, Sterz R, Matiba B, Bergemann R . Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ 2006; 7: 276\u2013284.","journal-title":"Eur J Health Econ"},{"key":"BFijo2008189_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0272989X03261565","volume":"24","author":"E Warren","year":"2004","unstructured":"Warren E, Brennan A, Akehurst R . Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004; 24: 9\u201319.","journal-title":"Med Decis Making"},{"key":"BFijo2008189_CR22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.18553\/jmcp.2005.11.6.458","volume":"11","author":"DC Malone","year":"2005","unstructured":"Malone DC, Raebel MA, Porter JA, Lanty FA, Conner DA, Gay EC et al. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. J Manag Care Pharm 2005; 11: 458\u2013468.","journal-title":"J Manag Care Pharm"},{"key":"BFijo2008189_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1467-789X.2005.00211.x","volume":"6","author":"DR Foxcroft","year":"2005","unstructured":"Foxcroft DR . Orlistat for the treatment of obesity: cost utility model. Obes Rev 2005; 6: 323\u2013328.","journal-title":"Obes Rev"},{"key":"BFijo2008189_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/sj.ijo.0802947","volume":"29","author":"LA Lacey","year":"2005","unstructured":"Lacey LA, Wolf A, O\u2019Shea D, Erny S, Ruof J . Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond) 2005; 29: 975\u2013982.","journal-title":"Int J Obes (Lond)"},{"key":"BFijo2008189_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2337\/diacare.25.2.303","volume":"25","author":"M Lamotte","year":"2002","unstructured":"Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J . A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303\u2013308.","journal-title":"Diabetes Care"},{"key":"BFijo2008189_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2165\/00019053-200321070-00005","volume":"21","author":"A Maetzel","year":"2003","unstructured":"Maetzel A, Ruof J, Covington M, Wolf A . Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21: 501\u2013512.","journal-title":"Pharmacoeconomics"},{"key":"BFijo2008189_CR27","first-page":"1","volume":"5","author":"S O\u2019Meara","year":"2001","unstructured":"O\u2019Meara S, Riemsma R, Shirran L, Mather L, ter Riet G . A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1\u201381.","journal-title":"Health Technol Assess"},{"key":"BFijo2008189_CR28","first-page":"1","volume":"6","author":"S O\u2019Meara","year":"2002","unstructured":"O\u2019Meara S, Riemsma R, Shirran L, Mather L, ter Riet G . The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002; 6: 1\u201397.","journal-title":"Health Technol Assess"},{"key":"BFijo2008189_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/sj.ijo.0802925","volume":"29","author":"J Ruof","year":"2005","unstructured":"Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A . Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond) 2005; 29: 517\u2013523.","journal-title":"Int J Obes (Lond)"},{"key":"BFijo2008189_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1524-4733.2007.00281.x","volume":"11","author":"C Hampp","year":"2008","unstructured":"Hampp C, Hartzema AG, Kauf TL . Cost-utility analysis of rimonabant in the treatment of obesity. Value Health 2008; 11: 389\u2013399.","journal-title":"Value Health"},{"key":"BFijo2008189_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/030079908X253591","volume":"24","author":"S Iannazzo","year":"2008","unstructured":"Iannazzo S, Zaniolo O, Pradelli L . Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin 2008; 24: 63\u201374.","journal-title":"Curr Med Res Opin"},{"key":"BFijo2008189_CR32","doi-asserted-by":"crossref","unstructured":"van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM . Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 2008. [e-pub ahead of print].","DOI":"10.1111\/j.1524-4733.2008.00328.x"},{"key":"BFijo2008189_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1467-789x.2000.00011.x","volume":"1","author":"DR Foxcroft","year":"2000","unstructured":"Foxcroft DR, Milne R . Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 2000; 1: 121\u2013126.","journal-title":"Obes Rev"},{"key":"BFijo2008189_CR34","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta8210","volume":"8","author":"A Avenell","year":"2004","unstructured":"Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii\u2013iiv, 1\u2013182.","journal-title":"Health Technol Assess"},{"key":"BFijo2008189_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2165\/00019053-200523100-00004","volume":"23","author":"P Hertzman","year":"2005","unstructured":"Hertzman P . The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics 2005; 23: 1007\u20131020.","journal-title":"Pharmacoeconomics"},{"key":"BFijo2008189_CR36","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2337\/diacare.25.10.1899-a","volume":"25","author":"J Edelsberg","year":"2002","unstructured":"Edelsberg J, Weycker D, Oster G . Response to Lamotte et al. \u2018A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients\u2019. Diabetes Care 2002; 25: 1899\u20131900.","journal-title":"Diabetes Care"},{"key":"BFijo2008189_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","volume":"20","author":"AM Heck","year":"2000","unstructured":"Heck AM, Yanovski JA, Calis KA . Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270\u2013279.","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"BFijo2008189_CR38","first-page":"S3","volume":"22","author":"T Kurscheid","year":"1998","unstructured":"Kurscheid T, Lauterbach K . The cost implications of obesity for health care and society. Int J Obes Relat Metab Disord 1998; 22 (Suppl 1): S3\u2013S5; discussion S6.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFijo2008189_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1345\/aph.1E081","volume":"39","author":"DC Anderson Jr","year":"2005","unstructured":"Anderson Jr DC . Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 2005; 39: 102\u2013109.","journal-title":"Ann Pharmacother"},{"key":"BFijo2008189_CR40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.aca.2007.03.007","volume":"589","author":"F Lu","year":"2007","unstructured":"Lu F, Li S, Le J, Chen G, Cao Y, Qi Y et al. A new method for testing synthetic drugs adulterated in herbal medicines based on infrared spectroscopy. Anal Chim Acta 2007; 589: 200\u2013207.","journal-title":"Anal Chim Acta"},{"key":"BFijo2008189_CR41","unstructured":"Foxcroft DR, Ludders J . Orlistat for the treatment of obesity, Southampton: Wessex Institute for Health Research and Development, Development and Evaluation Committee Report no. 101, 1999, September."},{"key":"BFijo2008189_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235\u2013242.","journal-title":"JAMA"},{"key":"BFijo2008189_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167\u2013172.","journal-title":"Lancet"},{"key":"BFijo2008189_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","volume":"24","author":"N Finer","year":"2000","unstructured":"Finer N, James WP, Kopelman PG, Lean ME, Williams G . One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306\u2013313.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFijo2008189_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/oby.2000.8","volume":"8","author":"S Rossner","year":"2000","unstructured":"Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G . Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49\u201361.","journal-title":"Obes Res"},{"key":"BFijo2008189_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00019053-200220060-00004","volume":"20","author":"Z Hakim","year":"2002","unstructured":"Hakim Z, Wolf A, Garrison LP . Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics 2002; 20: 393\u2013404.","journal-title":"Pharmacoeconomics"},{"key":"BFijo2008189_CR47","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","volume":"69","author":"JO Hill","year":"1999","unstructured":"Hill JO, Hauptman J, Anderson JW, Fujioka K, O\u2019Neil PM, Smith DK et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108\u20131116.","journal-title":"Am J Clin Nutr"},{"key":"BFijo2008189_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/archfami.9.2.160","volume":"9","author":"J Hauptman","year":"2000","unstructured":"Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR . Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160\u2013167.","journal-title":"Arch Fam Med"},{"key":"BFijo2008189_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1463-1326.2002.00237.x","volume":"4","author":"M Hanefeld","year":"2002","unstructured":"Hanefeld M, Sachse G . The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415\u2013423.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo2008189_CR50","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","volume":"21","author":"PA Hollander","year":"1998","unstructured":"Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288\u20131294.","journal-title":"Diabetes Care"},{"key":"BFijo2008189_CR51","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","volume":"25","author":"DE Kelley","year":"2002","unstructured":"Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033\u20131041.","journal-title":"Diabetes Care"},{"key":"BFijo2008189_CR52","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","volume":"25","author":"JM Miles","year":"2002","unstructured":"Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123\u20131128.","journal-title":"Diabetes Care"},{"key":"BFijo2008189_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405\u2013412.","journal-title":"BMJ"},{"key":"BFijo2008189_CR54","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854\u2013865.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"BFijo2008189_CR55","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2337\/diacare.15.7.820","volume":"15","author":"P Koskinen","year":"1992","unstructured":"Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH . Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820\u2013825.","journal-title":"Diabetes Care"},{"key":"BFijo2008189_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155\u2013161.","journal-title":"Diabetes Care"},{"issue":"1\u2009Part 2","key":"BFijo2008189_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Odell PM, Wilson PW, Kannel WB . Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1\u2009Part 2): 293\u2013298.","journal-title":"Am Heart J"},{"key":"BFijo2008189_CR58","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1524-4733.2004.71313.x","volume":"7","author":"J Latour-Perez","year":"2004","unstructured":"Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M . Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health 2004; 7: 52\u201360.","journal-title":"Value Health"},{"key":"BFijo2008189_CR59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/oby.2002.111","volume":"10","author":"EH Livingston","year":"2002","unstructured":"Livingston EH, Ko CY . Use of the health and activities limitation index as a measure of quality of life in obesity. Obes Res 2002; 10: 824\u2013832.","journal-title":"Obes Res"},{"key":"BFijo2008189_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00024677-200302020-00005","volume":"2","author":"C Lucioni","year":"2003","unstructured":"Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G . The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2: 121\u2013133.","journal-title":"Treat Endocrinol"},{"key":"BFijo2008189_CR61","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1007\/s00125-002-0861-2","volume":"45","author":"M Koopmanschap","year":"2002","unstructured":"Koopmanschap M . Coping with type II diabetes: the patient's perspective. Diabetologia 2002; 45: S18\u2013S22.","journal-title":"Diabetologia"},{"key":"BFijo2008189_CR62","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z Li","year":"2005","unstructured":"Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532\u2013546.","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"BFijo2008189_CR63","doi-asserted-by":"publisher","first-page":"290S","DOI":"10.1038\/oby.2001.133","volume":"9","author":"N Finer","year":"2001","unstructured":"Finer N . Low-calorie diets and sustained weight loss. Obes Res 2001; 9 (Suppl 4): 290S\u2013294S.","journal-title":"Obes Res"},{"key":"BFijo2008189_CR64","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ajcn\/74.5.579","volume":"74","author":"JW Anderson","year":"2001","unstructured":"Anderson JW, Konz EC, Frederich RC, Wood CL . Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579\u2013584.","journal-title":"Am J Clin Nutr"},{"key":"BFijo2008189_CR65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1478-7954-4-14","volume":"4","author":"PH van Baal","year":"2006","unstructured":"van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC . Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metr 2006; 4: 14.","journal-title":"Popul Health Metr"},{"key":"BFijo2008189_CR66","first-page":"505","volume":"50","author":"IG Smith","year":"2001","unstructured":"Smith IG, Goulder MA . Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505\u2013512.","journal-title":"J Fam Pract"},{"key":"BFijo2008189_CR67","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WP James","year":"2000","unstructured":"James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119\u20132125.","journal-title":"Lancet"},{"key":"BFijo2008189_CR68","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/j.1550-8528.1999.tb00436.x","volume":"7","author":"CD Sjostrom","year":"1999","unstructured":"Sjostrom CD, Lissner L, Wedel H, Sjostrom L . Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477\u2013484.","journal-title":"Obes Res"},{"key":"BFijo2008189_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7326\/0003-4819-122-7-199504010-00001","volume":"122","author":"GA Colditz","year":"1995","unstructured":"Colditz GA, Willett WC, Rotnitzky A, Manson JE . Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481\u2013486.","journal-title":"Ann Intern Med"},{"key":"BFijo2008189_CR70","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/01.CIR.83.1.356","volume":"83","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Wilson PW, Odell PM, Kannel WB . An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356\u2013362.","journal-title":"Circulation"},{"key":"BFijo2008189_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-2004-817934","volume":"112","author":"H Hauner","year":"2004","unstructured":"Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group SA . Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes 2004; 112: 201\u2013207.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"BFijo2008189_CR72","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","volume":"286","author":"A Wirth","year":"2001","unstructured":"Wirth A, Krause J . Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331\u20131339.","journal-title":"JAMA"},{"key":"BFijo2008189_CR73","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","volume":"67","author":"HB Hubert","year":"1983","unstructured":"Hubert HB, Feinleib M, McNamara PM, Castelli WP . Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968\u2013977.","journal-title":"Circulation"},{"key":"BFijo2008189_CR74","first-page":"369","volume":"10","author":"JA Porter","year":"2004","unstructured":"Porter JA, Raebel MA, Conner DA, Lanty FA, Vogel EA, Gay EC et al. The long-term outcomes of sibutramine effectiveness on weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004; 10: 369\u2013376.","journal-title":"Am J Manag Care"},{"key":"BFijo2008189_CR75","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761\u2013775.","journal-title":"JAMA"},{"key":"BFijo2008189_CR76","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121\u20132134.","journal-title":"N Engl J Med"},{"key":"BFijo2008189_CR77","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389\u20131397.","journal-title":"Lancet"},{"key":"BFijo2008189_CR78","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/jech.2003.015651","volume":"59","author":"SG Wannamethee","year":"2005","unstructured":"Wannamethee SG, Shaper AG, Walker M . Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005; 59: 134\u2013139.","journal-title":"J Epidemiol Community Health"},{"key":"BFijo2008189_CR79","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa010492","volume":"345","author":"FB Hu","year":"2001","unstructured":"Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790\u2013797.","journal-title":"N Engl J Med"},{"key":"BFijo2008189_CR80","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jama.280.21.1843","volume":"280","author":"KM Rexrode","year":"1998","unstructured":"Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843\u20131848.","journal-title":"JAMA"},{"key":"BFijo2008189_CR81","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/sj.ijo.0801615","volume":"25","author":"KM Rexrode","year":"2001","unstructured":"Rexrode KM, Buring JE, Manson JE . Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001; 25: 1047\u20131056.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFijo2008189_CR82","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","volume":"316","author":"P Kind","year":"1998","unstructured":"Kind P, Dolan P, Gudex C, Williams A . Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736\u2013741.","journal-title":"BMJ"},{"key":"BFijo2008189_CR83","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jama.1978.03290150053024","volume":"240","author":"R Stamler","year":"1978","unstructured":"Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH . Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240: 1607\u20131610.","journal-title":"JAMA"},{"key":"BFijo2008189_CR84","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC . Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194\u20131199.","journal-title":"BMJ"},{"key":"BFijo2008189_CR85","first-page":"875","volume":"7","author":"GP Samsa","year":"2001","unstructured":"Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM . Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care 2001; 7: 875\u2013883.","journal-title":"Am J Manag Care"},{"key":"BFijo2008189_CR86","unstructured":"Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2), 2007. Accessed 20 October 2008, available at: http:\/\/www.lfn.se\/upload\/Foretag\/ENG_lfnar2003-eng.pdf"},{"key":"BFijo2008189_CR87","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1467-789X.2008.00463.x","volume":"9","author":"M Neovius","year":"2008","unstructured":"Neovius M, Johansson K, Rossner S . Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008; 9: 420\u2013427.","journal-title":"Obes Rev"},{"key":"BFijo2008189_CR88","volume-title":"Contemporary Diagnosis and Management of Obesity","author":"GA Bray","year":"2003","unstructured":"Bray GA . Contemporary Diagnosis and Management of Obesity, 2nd edn. Handbooks in Health Care Co.: Newtown, PA, 2003."},{"key":"BFijo2008189_CR89","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","volume":"160","author":"FG McMahon","year":"2000","unstructured":"McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185\u20132191.","journal-title":"Arch Intern Med"},{"key":"BFijo2008189_CR90","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","volume":"16","author":"FG McMahon","year":"2002","unstructured":"McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K . Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5\u201311.","journal-title":"J Hum Hypertens"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ijo2008189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo2008189","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo2008189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:18:20Z","timestamp":1684430300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo2008189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,4]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["BFijo2008189"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2008.189","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,4]]}}}